Company: Galapagos NV

Bloomberg ticker: GLPG NA

Market cap: US$2,722m

Background: Galapagos NV is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action, with a pipeline comprising Phase 3, 2, 1, pre-clinical and discovery studies in cystic fibrosis, inflammation, fibrosis, osteoarthritis, and other indications.

World Class Benchmarking of Galapagos NV

---

---

 

• Profitable Growth rank of 9 was same compared to the prior period’s 9th rank
• This is poor performance compared to 410 medium Health Care companies worldwide.
• Profitability rank of 9 was better than its Growth rank of 10
• Profitability rank of 9 was the same compared to the prior period’s 9th rank
• This is poor performance compared to peers
• Growth rank of 10 was the same compared to the prior period’s 10th rank
• This is poor performance compared to peers

 

---

DISCLAIMER: This content is for information purposes only. It is not intended to be investment advice. Readers should not consider statements made by the author(s) as formal recommendations and should consult their financial advisor before making any investment decisions. While the information provided is believed to be accurate, it may include errors or inaccuracies. The author(s) cannot be held liable for any actions taken as a result of reading this article.